Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.927
Filter
1.
Molecules ; 28(18)2023 Sep 15.
Article in English | MEDLINE | ID: mdl-37764419

ABSTRACT

One of the most essential health problems is cancer, the first or second cause of death worldwide. Head and neck cancers are hard to detect due to non-specific symptoms. The treatment often relies on a combination of radio and chemotherapy. For this reason, the research of new anticancer compounds is fundamental. The natural and synthetic compounds with 1,4-naphthoquinone scaffold is characterized by high anticancer activity. The study aimed to evaluate the synthesis and anticancer activity of hybrids 1,4-naphthoquinone with thymidine derivatives. The series of compounds allows us to check the influence of the substituent in the C3' position of the thymidine moiety on the cytotoxicity against squamous cancer cell lines (SCC-9 and SCC-25) and submandibular gland cancer (A-253). An annexin V/propidium iodide (PI) co-staining assay shows that derivatives cause the apoptotic in SCC-25 and A-253 cell lines. The molecular docking study examined the interaction between the active site of the BCL-2 protein and the hybrids.


Subject(s)
Antineoplastic Agents , Head and Neck Neoplasms , Humans , Molecular Docking Simulation , Antineoplastic Agents/chemistry , Thymidine/pharmacology , Cell Line, Tumor , Drug Screening Assays, Antitumor , Cell Proliferation , Molecular Structure , Apoptosis , Structure-Activity Relationship
2.
J Biol Chem ; 297(5): 101345, 2021 11.
Article in English | MEDLINE | ID: mdl-34717955

ABSTRACT

Detection of thymidine analogues after their incorporation into replicating DNA represents a powerful tool for the study of cellular DNA synthesis, progression through the cell cycle, cell proliferation kinetics, chronology of cell division, and cell fate determination. Recent advances in the concurrent detection of multiple such analogues offer new avenues for the investigation of unknown features of these vital cellular processes. Combined with quantitative analysis, temporal discrimination of multiple labels enables elucidation of various aspects of stem cell life cycle in situ, such as division modes, differentiation, maintenance, and elimination. Data obtained from such experiments are critically important for creating descriptive models of tissue histogenesis and renewal in embryonic development and adult life. Despite the wide use of thymidine analogues in stem cell research, there are a number of caveats to consider for obtaining valid and reliable labeling results when marking replicating DNA with nucleotide analogues. Therefore, in this review, we describe critical points regarding dosage, delivery, and detection of nucleotide analogues in the context of single and multiple labeling, outline labeling schemes based on pulse-chase, cumulative and multilabel marking of replicating DNA for revealing stem cell proliferative behaviors, and determining cell cycle parameters, and discuss preconditions and pitfalls in conducting such experiments. The information presented in our review is important for rational design of experiments on tracking dividing stem cells by marking replicating DNA with thymidine analogues.


Subject(s)
Cell Cycle , Cell Self Renewal , Cell Tracking , DNA Replication , Stem Cells , Thymidine , Animals , Humans , Stem Cells/cytology , Stem Cells/metabolism , Thymidine/analogs & derivatives , Thymidine/chemistry , Thymidine/pharmacology
3.
Arch Biochem Biophys ; 729: 109377, 2022 Oct 30.
Article in English | MEDLINE | ID: mdl-35998686

ABSTRACT

Alzheimer's disease (AD) is a progressive disease with a long duration and complicated pathogenesis. Thymidine (Thy) and 2'-deoxyuridine (2'-De) are pyrimidines nucleotides that are associated with nervous system diseases. However, it remains unclear whether Thy and 2'-De exert neuroprotective effects in AD. Therefore, this study was conducted to explore the interventional effects and mechanisms of Thy and 2'-De on the Aß25-35-induced brain injury. Donepezil (Do, 10 mg/kg/d), Thy (20 mg/kg/d), and 2'-De (20 mg/kg/d) were administered for 4 weeks after the injection of Aß25-35 peptides (200 µM, i.c.v.) to mice. UPLC-MS/MS method was performed to quantify Thy and 2'-De in the hippocampus of mice brain. The cognition ability, neuronal and mitochondria damage, and levels of Aß1-42/Aß1-40, p-Tau, Na+ K+-ATPase, apoptosis, oxidative stress, immune cells, and Iba 1+ were measured in Aß25-35-induced mice. The oxygen consumption (OCR) and extracellular acidification rate (ECAR) were measured using a seahorse analyzer in Aß25-35-induced N9 cells. Moreover, 2-Deoxy-D-glucose (2-DG), a glycolysis inhibitor, was added to explore the mechanisms underlying the effects of Thy and 2'-De on Aß25-35-induced N9 cells. The expression of Iba 1+ and levels of CD11b+ and reactive oxygen species (ROS) were measured after treatment with Thy (5 µM) and 2'-De (10 µM) against 2-DG (5 mM) in Aß25-35-induced N9 cells. The results suggested that Do, Thy, and 2'-De improved the cognition ability, attenuated the damage to hippocampus and mitochondria, downregulated the levels of Aß1-42/Aß1-40, p-Tau, Na+ K+-ATPase, apoptosis, oxidative stress, and Iba 1+, and regulated the immune response induced by Aß25-35 against the brain injury. Furthermore, Do, Thy, and 2'-De increased ATP production and inhibited glycolysis in Aß25-35-induced N9 cells. Moreover, 2-DG enhanced the effects of drugs, reduced microglial activation, and attenuated oxidative stress to interfere with Aß25-35-induced N9 cells. In conclusion, Thy and 2'-De reduced microglial activation and improved oxidative stress damage by modulating glycolytic metabolism on the Aß25-35-induced brain injury.


Subject(s)
Alzheimer Disease , Brain Injuries , Neuroprotective Agents , Adenosine Triphosphatases/metabolism , Adenosine Triphosphate/metabolism , Alzheimer Disease/chemically induced , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Animals , Apoptosis , Chromatography, Liquid , Deoxyglucose/pharmacology , Deoxyuridine/metabolism , Deoxyuridine/pharmacology , Donepezil/pharmacology , Glycolysis , Mice , Microglia/metabolism , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Nucleotides/metabolism , Oxidative Stress , Peptide Fragments/metabolism , Pyrimidines/pharmacology , Reactive Oxygen Species/metabolism , Tandem Mass Spectrometry , Thymidine/metabolism , Thymidine/pharmacology
4.
Bioorg Med Chem ; 60: 116690, 2022 04 15.
Article in English | MEDLINE | ID: mdl-35259549

ABSTRACT

A gapmer-type antisense oligonucleotide is an oligonucleotide therapeutic that targets pathogenic mRNA directly, and it is expected to be a next-generation therapeutic drug. In this study, we designed and synthesized 4'-C-[(N-methyl)aminoethyl]-thymidine (4'-MAE-T) as a novel nucleoside analog and compared its properties with those of 4'-C-aminoethyl-thymidine (4'-AE-T). Furthermore, we designed a new synthetic route for 4'-C-aminoethyl-modified nucleosides and accomplished the synthesis of 4'-AE-T via a novel pathway with high total yield. DNA containing 4'-MAE-T analogs decreased RNA affinity slightly more than unmodified DNA and DNA containing 4'-AE-T, but significantly improved nuclease resistance compared to unmodified DNA in a solution containing bovine serum. In addition, the impact of 4'-MAE-T on DNA stability was higher than that of 4'-AE-T. Also, DNA containing these analogs can activate Escherichia coli-derived RNase H. Thus, 4'-MAE-T has the potential to be used in gapmer-type antisense nucleic acids as a suitable candidate for the development of therapeutic antisense oligonucleotides.


Subject(s)
DNA , Nucleosides , Escherichia coli/metabolism , Nucleosides/pharmacology , Oligonucleotides , Oligonucleotides, Antisense/pharmacology , RNA/metabolism , Ribonuclease H/metabolism , Thymidine/pharmacology
5.
Bioorg Chem ; 125: 105850, 2022 08.
Article in English | MEDLINE | ID: mdl-35533581

ABSTRACT

Nucleoside precursors and nucleoside analogs occupy an important place in the treatment of viral respiratory pathologies, especially during the current COVID-19 pandemic. From this perspective, the present study has been designed to explore and evaluate the synthesis and spectral characterisation of 5́-O-(lauroyl) thymidine analogs 2-6 with different aliphatic and aromatic groups through comprehensive in vitro antimicrobial screening, cytotoxicity assessment, physicochemical aspects, molecular docking and molecular dynamics analysis, along with pharmacokinetic prediction. A unimolar one-step lauroylation of thymidine under controlled conditions furnished the 5́-O-(lauroyl) thymidine and indicated the selectivity at C-5́ position and the development of thymidine based potential antimicrobial analogs, which were further converted into four newer 3́-O-(acyl)-5́-O-(lauroyl) thymidine analogs in reasonably good yields. The chemical structures of the newly synthesised analogs were ascertained by analysing their physicochemical, elemental, and spectroscopic data. In vitro antimicrobial tests against five bacteria and two fungi, along with the prediction of activity spectra for substances (PASS), indicated promising antibacterial functionality for these thymidine analogs compared to antifungal activity. In support of this observation, molecular docking experiments have been performed against the main protease of SARS-CoV-2, and significant binding affinities and non-bonding interactions were observed against the main protease (6LU7, 6Y84 and 7BQY), considering hydroxychloroquine (HCQ) as standard. Moreover, the 100 ns molecular dynamics simulation process was performed to monitor the behaviour of the complex structure formed by the main protease under in silico physiological conditions to examine its stability over time, and this revealed a stable conformation and binding pattern in a stimulating environment of thymidine analogs. Cytotoxicity determination confirmed that compounds were found less toxic. Pharmacokinetic predictions were investigated to evaluate their absorption, distribution, metabolism and toxic properties, and the combination of pharmacokinetic and drug-likeness predictions has shown promising results in silico. The POM analysis shows the presence of an antiviral (O1δ-, O2δ-) pharmacophore site. Overall, the current study should be of great help in the development of thymidine-based, novel, multiple drug-resistant antimicrobial and COVID-19 drugs.


Subject(s)
COVID-19 Drug Treatment , SARS-CoV-2 , Anti-Bacterial Agents , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Coronavirus 3C Proteases , Cysteine Endopeptidases/metabolism , Humans , Molecular Docking Simulation , Molecular Dynamics Simulation , Pandemics , Protease Inhibitors/chemistry , Thymidine/pharmacology , Viral Nonstructural Proteins/metabolism
6.
Int J Mol Sci ; 23(13)2022 Jun 27.
Article in English | MEDLINE | ID: mdl-35806135

ABSTRACT

Cancer stem cells (CSCs) are resistant to conventional therapy and present a major clinical challenge since they are responsible for the relapse of many cancers, including non-small cell lung cancer (NSCLC). Hence, future successful therapy should also eradicate CSCs. Auger electrons have demonstrated promising therapeutic potential and can induce DNA damage while sparing surrounding cells. Here, we sort primary patient-derived NSCLC cells based on their expression of the CSC-marker CD44 and investigate the effects of cisplatin and a thymidine analog (deoxyuridine) labeled with an Auger electron emitter (125I). We show that the CD44+ populations are more resistant to cisplatin than the CD44- populations. Interestingly, incubation with the thymidine analog 5-[125I]iodo-2'-deoxyuridine ([125I]I-UdR) induces equal DNA damage, G2/M cell cycle arrest, and apoptosis in the CD44- and CD44+ populations. Our results suggest that Auger electron emitters can also eradicate resistant lung cancer CD44+ populations.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Carcinoma, Non-Small-Cell Lung/genetics , Cell Line, Tumor , Cisplatin/therapeutic use , Deoxyuridine , Electrons , Humans , Hyaluronan Receptors/metabolism , Lung Neoplasms/metabolism , Neoplasm Recurrence, Local/drug therapy , Neoplastic Stem Cells/metabolism , Thymidine/pharmacology
7.
Int J Mol Sci ; 23(16)2022 Aug 17.
Article in English | MEDLINE | ID: mdl-36012530

ABSTRACT

Immune checkpoint inhibitors (ICIs) are widely used in cancer immunotherapy, requiring effective methods for response monitoring. This study evaluated changes in 18F-2-fluoro-2-deoxy-D-glucose (FDG) and 18F-fluorothymidine (FLT) uptake by tumors following ICI treatment as potential imaging biomarkers in mice. Tumor uptakes of 18F-FDG and 18F-FLT were measured and compared between the ICI treatment and control groups. A combined imaging index of glucose-thymidine uptake ratio (GTR) was defined and compared between groups. In the ICI treatment group, tumor growth was effectively inhibited, and higher proportions of immune cells were observed. In the early phase, 18F-FDG uptake was higher in the treatment group, whereas 18F-FLT uptake was not different. There was no difference in 18F-FDG uptake between the two groups in the late phase. However, 18F-FLT uptake of the control group was markedly increased compared with the ICI treatment group. GTR was consistently higher in the ICI treatment group in the early and late phases. After ICI treatment, changes in tumor cell proliferation were observed with 18F-FLT, whereas 18F-FDG showed altered metabolism in both tumor and immune cells. A combination of 18F-FLT and 18F-FDG PET, such as GTR, is expected to serve as a potentially effective imaging biomarker for monitoring ICI treatment.


Subject(s)
Fluorodeoxyglucose F18 , Neoplasms , Animals , Biomarkers , Dideoxynucleosides , Fluorodeoxyglucose F18/therapeutic use , Glucose/therapeutic use , Immune Checkpoint Inhibitors/pharmacology , Immune Checkpoint Inhibitors/therapeutic use , Mice , Neoplasms/diagnostic imaging , Neoplasms/drug therapy , Positron-Emission Tomography/methods , Radiopharmaceuticals/therapeutic use , Thymidine/pharmacology
8.
Nucleic Acids Res ; 47(1): 103-121, 2019 01 10.
Article in English | MEDLINE | ID: mdl-30321399

ABSTRACT

The oncogenic transcription factor B-Myb is an essential regulator of late cell cycle genes whose activation by phosphorylation is still poorly understood. We describe a stepwise phosphorylation mechanism of B-Myb, which involves sequential phosphorylations mediated by cyclin-dependent kinase (Cdk) and Polo-like kinase 1 (Plk1) and Pin1-facilitated peptidyl-prolyl cis/trans isomerization. Our data suggest a model in which initial Cdk-dependent phosphorylation of B-Myb enables subsequent Pin1 binding and Pin1-induced conformational changes of B-Myb. This, in turn, initiates further phosphorylation of Cdk-phosphosites, enabling Plk1 docking and subsequent Plk1-mediated phosphorylation of B-Myb to finally allow B-Myb to stimulate transcription of late cell cycle genes. Our observations reveal novel mechanistic hierarchies of B-Myb phosphorylation and activation and uncover regulatory principles that might also apply to other Myb family members. Strikingly, overexpression of B-Myb and of factors mediating its activation strongly correlates with adverse prognoses for tumor patients, emphasizing B-Myb's role in tumorigenesis.


Subject(s)
Cell Cycle Proteins/genetics , NIMA-Interacting Peptidylprolyl Isomerase/genetics , Neoplasms/genetics , Protein Serine-Threonine Kinases/genetics , Proto-Oncogene Proteins/genetics , Trans-Activators/genetics , Carcinogenesis/drug effects , Cell Cycle/genetics , Cell Cycle Proteins/antagonists & inhibitors , Cell Cycle Proteins/chemistry , Cyclin-Dependent Kinases/antagonists & inhibitors , Cyclin-Dependent Kinases/genetics , Gene Expression Regulation, Neoplastic/drug effects , HeLa Cells , Hep G2 Cells , Humans , Mitosis/drug effects , NIMA-Interacting Peptidylprolyl Isomerase/antagonists & inhibitors , NIMA-Interacting Peptidylprolyl Isomerase/chemistry , Neoplasms/drug therapy , Neoplasms/pathology , Nocodazole/pharmacology , Peptidylprolyl Isomerase/genetics , Phosphorylation/drug effects , Protein Conformation/drug effects , Protein Multimerization/drug effects , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/chemistry , Proto-Oncogene Proteins/antagonists & inhibitors , Proto-Oncogene Proteins/chemistry , Roscovitine/pharmacology , Thymidine/pharmacology , Trans-Activators/chemistry , Transcription, Genetic/drug effects , Polo-Like Kinase 1
9.
Molecules ; 26(16)2021 Aug 23.
Article in English | MEDLINE | ID: mdl-34443682

ABSTRACT

Atherosclerosis is the main cause of cardiovascular diseases which in turn, lead to the highest number of mortalities globally. This pathophysiological condition is developed due to a constant elevated level of plasma cholesterols. Statin is currently the widely used treatment in reducing the level of cholesterols, however, it may cause adverse side effects. Therefore, there is an urgent need to search for new alternative treatment. PCSK9 is an enzyme responsible in directing LDL-receptor (LDL-R)/LDL-cholesterols (LDL-C) complex to lysosomal degradation, preventing the receptor from recycling back to the surface of liver cells. Therefore, PCSK9 offers a potential target to search for small molecule inhibitors which inhibit the function of this enzyme. In this study, a marine invertebrate Acanthaster planci, was used to investigate its potential in inhibiting PCSK9 and lowering the levels of cholesterols. Cytotoxicity activity of A. planci on human liver HepG2 cells was carried out using the MTS assay. It was found that methanolic extract and fractions did not exhibit cytotoxicity effect on HepG2 cell line with IC50 values of more than 30 µg/mL. A compound deoxythymidine also did not exert any cytotoxicity activity with IC50 value of more than 4 µg/mL. Transient transfection and luciferase assay were conducted to determine the effects of A. planci on the transcriptional activity of PCSK9 promoter. Methanolic extract and Fraction 2 (EF2) produced the lowest reduction in PCSK9 promoter activity to 70 and 20% of control at 12.5 and 6.25 µg/mL, respectively. In addition, deoxythymidine also decreased PCSK9 promoter activity to the lowest level of 60% control at 3.13 µM. An in vivo study using Sprague Dawley rats demonstrated that 50 and 100 mg/kg of A. planci methanolic extract reduced the total cholesterols and LDL-C levels to almost similar levels of untreated controls. The level of serum glutamate oxalate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) showed that the administration of the extract did not produce any toxicity effect and cause any damage to rat liver. The results strongly indicate that A. planci produced a significant inhibitory activity on PCSK9 gene expression in HepG2 cells which may be responsible for inducing the uptake of cholesterols by liver, thus, reducing the circulating levels of total cholesterols and LDL-C. Interestingly, A. planci also did show any adverse hepato-cytotoxicity and toxic effects on liver. Thus, this study strongly suggests that A. planci has a vast potential to be further developed as a new class of therapeutic agent in lowering the blood cholesterols and reducing the progression of atherosclerosis.


Subject(s)
Cholesterol/blood , PCSK9 Inhibitors , Starfish/chemistry , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Cell Death , Cell Proliferation , Cholesterol, LDL/blood , Hep G2 Cells , Humans , Luciferases/metabolism , Male , Methanol , Promoter Regions, Genetic/genetics , Proprotein Convertase 9/genetics , Proprotein Convertase 9/metabolism , Rats, Sprague-Dawley , Thymidine/pharmacology , Triglycerides/blood
10.
Bull Exp Biol Med ; 171(4): 449-452, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34542749

ABSTRACT

Culturing of Mycoplasma hominis in the presence of arginine and thymidine and subsequent comparative proteomic analysis of cells showed that, in addition to the already known arginine dihydrolase pathway of energy metabolism, M. hominis can utilize deoxyribose phosphates formed as a result of catabolism of pyrimidine nucleosides. In this case, a sharp deceleration of cell growth was observed. This allows M. hominis to occupy new niches in the host organism and survive under competitive conditions when the main sources of energy are unavailable.


Subject(s)
Carbon/pharmacology , Culture Media/pharmacology , Mycoplasma hominis/metabolism , Proteome/analysis , Arginine/pharmacology , Bacteriological Techniques/methods , Culture Media/chemistry , Electrophoresis, Gel, Two-Dimensional , Humans , Mycoplasma Infections/metabolism , Mycoplasma Infections/microbiology , Mycoplasma hominis/chemistry , Mycoplasma hominis/drug effects , Mycoplasma hominis/growth & development , Proteome/drug effects , Proteome/metabolism , Proteomics/methods , Thymidine/pharmacology
11.
Bull Exp Biol Med ; 172(2): 245-249, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34853973

ABSTRACT

We compared the formation of γH2AX foci (marker of DNA double-strand breaks) in human lung fibroblasts (MRC-5 line) during their 24-h incubation in a medium containing 3H-labeled thymidine or amino acids (glycine, alanine, and proline) with specific radioactivity from 100 to 400 MBq/liter. A linear dependence of changes in the number of γH2AX foci on the specific radioactivity of the medium was revealed. The quantitative yield of DNA double-strand breaks under the influence of 3H-thymidine was more than 2-fold higher than under the influence of 3H-labeled amino acids. Comparative analysis of the yields of DNA double-strand breaks during cell incubation with 3H-labeled amino acids showed that 3H-alanine produced more pronounced effect that 3H-proline, which is consistent with the data on the content of their non-radioactive analogs in chromatin proteins.


Subject(s)
DNA Breaks, Double-Stranded , Fibroblasts , Histones/genetics , Lung , Tritium/pharmacology , Amino Acids/chemistry , Amino Acids/pharmacology , Cells, Cultured , Culture Media/chemistry , Culture Media/pharmacology , DNA Breaks, Double-Stranded/radiation effects , Fibroblasts/drug effects , Fibroblasts/metabolism , Fibroblasts/pathology , Fibroblasts/radiation effects , Histones/metabolism , Humans , Lung/drug effects , Lung/metabolism , Lung/pathology , Lung/radiation effects , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/radiation effects , Thymidine/chemistry , Thymidine/pharmacology , Tritium/chemistry
12.
Stem Cells ; 37(7): 876-887, 2019 07.
Article in English | MEDLINE | ID: mdl-30895693

ABSTRACT

In spite of the progress in gene editing achieved in recent years, a subset of genetic diseases involving structural chromosome abnormalities, including aneuploidies, large deletions and complex rearrangements, cannot be treated with conventional gene therapy approaches. We have previously devised a strategy, dubbed chromosome transplantation (CT), to replace an endogenous mutated chromosome with an exogenous normal one. To establish a proof of principle for our approach, we chose as disease model the chronic granulomatous disease (CGD), an X-linked severe immunodeficiency due to abnormalities in CYBB (GP91) gene, including large genomic deletions. We corrected the gene defect by CT in induced pluripotent stem cells (iPSCs) from a CGD male mouse model. The Hprt gene of the endogenous X chromosome was inactivated by CRISPR/Cas9 technology thus allowing the exploitation of the hypoxanthine-aminopterin-thymidine selection system to introduce a normal donor X chromosome by microcell-mediated chromosome transfer. X-transplanted clones were obtained, and diploid XY clones which spontaneously lost the endogenous X chromosome were isolated. These cells were differentiated toward the myeloid lineage, and functional granulocytes producing GP91 protein were obtained. We propose the CT approach to correct iPSCs from patients affected by other X-linked diseases with large deletions, whose treatment is still unsatisfactory. Stem Cells 2019;37:876-887.


Subject(s)
Chromosomes, Mammalian , Genetic Therapy/methods , Granulocytes/metabolism , Granulomatous Disease, Chronic/therapy , Hypoxanthine Phosphoribosyltransferase/genetics , Induced Pluripotent Stem Cells/metabolism , NADPH Oxidase 2/genetics , Aminopterin/metabolism , Aminopterin/pharmacology , Animals , Base Sequence , CRISPR-Cas Systems , Cell Differentiation , Clone Cells , Culture Media/chemistry , Disease Models, Animal , Gene Editing/methods , Granulocytes/cytology , Granulocytes/drug effects , Granulomatous Disease, Chronic/genetics , Granulomatous Disease, Chronic/metabolism , Granulomatous Disease, Chronic/pathology , Humans , Hypoxanthine/metabolism , Hypoxanthine/pharmacology , Hypoxanthine Phosphoribosyltransferase/deficiency , Induced Pluripotent Stem Cells/drug effects , Induced Pluripotent Stem Cells/pathology , Male , Mice , NADPH Oxidase 2/deficiency , Proof of Concept Study , Sequence Deletion , Thioguanine/metabolism , Thioguanine/pharmacology , Thymidine/metabolism , Thymidine/pharmacology , X Chromosome/chemistry , X Chromosome/metabolism
13.
Chem Res Toxicol ; 33(9): 2276-2285, 2020 09 21.
Article in English | MEDLINE | ID: mdl-32812424

ABSTRACT

DNA damage can occur naturally or through environmental factors, leading to mutations in DNA replication and genomic instability in cells. Normally, natural d-nucleotides were selected by DNA polymerases. The template l-thymidine (l-T) has been shown to be bypassed by several types of DNA polymerases. However, DNA replication fidelity of nucleotide incorporation opposite l-thymidine in vivo remains unknown. Here, we constructed plasmids containing a restriction enzyme (PstI) recognition site in which the l-T lesion was site-specifically located within the PstI recognition sequence (CTGCAG). Further, we assessed the efficiencies of nucleotide incorporation opposite the l-T site and l-T lesion bypass replication in vitro and in vivo. We found that recombinants containing the l-T lesion site inhibited DNA replication. In addition, A was incorporated opposite the l-T lesion by routine PCR assay, whereas preference for nucleotide incorporation opposite the l-T site was A (13%), T (22%), C (46%), and G (19%), and no nucleotide insertion and deletions were detected in E. coli cells. In particular, a novel restriction enzyme-mediated method for detection of the mutagenic properties of DNA lesion was established, which allows us to readily detect restriction-digestion of the l-T-bearing plasmids. The study provided significant insight into how mirror-image nucleosides perturb the fidelity of DNA replication in vivo and whether they elicit mutagenic effects, which may help to understand both how DNA damage interferes with the flow of genetic information during DNA replication and development of diseases caused by gene mutation.


Subject(s)
DNA Replication/drug effects , DNA, Bacterial/drug effects , Escherichia coli/drug effects , Thymidine/pharmacology , DNA Damage , DNA Replication/genetics , DNA, Bacterial/genetics , Escherichia coli/cytology
14.
Parasitol Res ; 119(1): 165-175, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31807868

ABSTRACT

A novel library of synthetic piperidine derivatives was used to screen against human lymphatic filarial parasite Brugia malayi. Piperidine has earlier been reported to have effect against parasites including rodent filarial nematodes. Compounds with hydroxyl substitutions (4Q and 4H) showed marked antifilarial effect. Molecular docking of 4H derivative showed more favorable thermodynamic parameters against thymidylate synthase of B. malayi than human counterpart. A wide difference between IC50 and LD50 ensured the therapeutic safety of the candidates against the filarial parasites. Addition of thymidine to the treatment regimen led to a significant reversal of antifilarial effect of 4H that confirmed inhibition of thymidylate synthase as pharmacological rationale. Apoptosis induced in the parasite as a consequence of probable inhibition of thymidylate synthase was studied by acridine orange/ethidium bromide fluorescent staining and poly (ADP-ribose) polymerase activity inhibition. Involvement of mitochondria was confirmed by decreased 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) conversion and increased cytosolic cytochrome c level in 4H treated microfilariae, compared with the untreated microfilariae. Moreover, Michael adduct of chalcone targeting dihydrofolate reductase and piperidine targeting thymidylate synthase demonstrated synergistic effect on the parasite, indicating the importance of inhibition of DNA synthesis by combined effect. In conclusion, piperidine derivatives with hydroxyl substitution have a great therapeutic potential with an apoptotic rationale involving mitochondrial pathway, due to possible inhibition of parasitic thymidylate synthase.


Subject(s)
Brugia malayi/drug effects , Elephantiasis, Filarial/drug therapy , Filaricides/pharmacology , Piperidines/pharmacology , Thymidylate Synthase/antagonists & inhibitors , Animals , Chalcone/pharmacology , DNA Replication/drug effects , Elephantiasis, Filarial/parasitology , Folic Acid Antagonists/pharmacology , Humans , Microfilariae/drug effects , Molecular Docking Simulation , Tetrahydrofolate Dehydrogenase/drug effects , Tetrazolium Salts , Thymidine/pharmacology
15.
Org Biomol Chem ; 17(9): 2403-2412, 2019 02 27.
Article in English | MEDLINE | ID: mdl-30735210

ABSTRACT

TBA is a 15-mer DNA aptamer for human α-thrombin, and its three T-rich loops are involved in the binding interactions with thrombin differently. In order to clarify their specific spatial locations in the binding interactions and search for more favourable positions, here a systematic investigation of all the loop residues was conducted with 3'-inverted thymidine (iT), by which both unnatural 3'-3'- and 5'-5'-linkages for each incorporation were introduced in the tertiary structure. The changes in Tm values and CD spectra revealed that motifs T3T12 and T4T13 are structurally distinct. Longer anti-clotting time was obtained for the T3 and T12 modifications, respectively, while T4 and T13 were completely intolerant with such changes, in terms of stability and binding to thrombin. In particular, the increased affinity bindings and longer anti-clotting time were obtained with the replacement on the central loop T7G8T9, which were closely related to the existence of a monovalent ion, K+ or Na+, consistently with the supposed binding site of these ions in TBA. It is worthwhile to note that both the subtle variations of the loop residues induced by iT and the monovalent ions determined the interacting residues of TBA and the binding strength rather than the thermal stability of the TBA structure.


Subject(s)
Aptamers, Nucleotide/metabolism , Thrombin/metabolism , Thymidine/metabolism , Anticoagulants/chemistry , Anticoagulants/metabolism , Anticoagulants/pharmacology , Aptamers, Nucleotide/chemistry , Aptamers, Nucleotide/pharmacology , Base Sequence , Binding Sites , Circular Dichroism , Humans , Molecular Docking Simulation , Molecular Dynamics Simulation , Nucleic Acid Conformation , Protein Binding , Temperature , Thymidine/chemistry , Thymidine/pharmacology
16.
Int J Mol Sci ; 20(7)2019 Apr 09.
Article in English | MEDLINE | ID: mdl-30970566

ABSTRACT

The mammalian mediator complex subunit 28 (MED28) is overexpressed in a variety of cancers and it regulates cell migration/invasion and epithelial-mesenchymal transition. However, transcription factors that increase MED28 expression have not yet been identified. In this study, we performed a luciferase reporter assay to identify and characterize the prospective transcription factors, namely E2F transcription factor 1, nuclear respiratory factor 1, E-26 transforming sequence 1, and CCAAT/enhancer-binding protein ß, which increased MED28 expression. In addition, the release from the arrest at the G1-S or G2-M phase transition after cell cycle synchronization using thymidine or nocodazole, respectively, showed enhanced MED28 expression at the G1-S transition and mitosis. Furthermore, the overexpression of MED28 significantly decreased the duration of interphase and mitosis. Conversely, a knockdown of MED28 using si-RNA increased the duration of interphase and mitosis. Of note, the overexpression of MED28 significantly increased micronucleus and nuclear budding in HeLa cells. In addition, flow cytometry and fluorescence microscopy analyses showed that the overexpression of MED28 significantly increased aneuploid cells. Taken together, these results suggest that MED28 expression is increased by oncogenic transcription factors and its overexpression disturbs the cell cycle, which results in genomic instability and aneuploidy.


Subject(s)
Genomic Instability , Mediator Complex/genetics , Mediator Complex/metabolism , Transcription Factors/metabolism , Aneuploidy , Cell Cycle/drug effects , Genomic Instability/drug effects , HEK293 Cells , HeLa Cells , Humans , MCF-7 Cells , Nocodazole/pharmacology , Promoter Regions, Genetic , Thymidine/pharmacology , Up-Regulation
17.
Ann Neurol ; 81(5): 641-652, 2017 May.
Article in English | MEDLINE | ID: mdl-28318037

ABSTRACT

OBJECTIVE: Thymidine kinase 2 (TK2), a critical enzyme in the mitochondrial pyrimidine salvage pathway, is essential for mitochondrial DNA (mtDNA) maintenance. Mutations in the nuclear gene, TK2, cause TK2 deficiency, which manifests predominantly in children as myopathy with mtDNA depletion. Molecular bypass therapy with the TK2 products, deoxycytidine monophosphate (dCMP) and deoxythymidine monophosphate (dTMP), prolongs the life span of Tk2-deficient (Tk2-/- ) mice by 2- to 3-fold. Because we observed rapid catabolism of the deoxynucleoside monophosphates to deoxythymidine (dT) and deoxycytidine (dC), we hypothesized that: (1) deoxynucleosides might be the major active agents and (2) inhibition of deoxycytidine deamination might enhance dTMP+dCMP therapy. METHODS: To test these hypotheses, we assessed two therapies in Tk2-/- mice: (1) dT+dC and (2) coadministration of the deaminase inhibitor, tetrahydrouridine (THU), with dTMP+dCMP. RESULTS: We observed that dC+dT delayed disease onset, prolonged life span of Tk2-deficient mice and restored mtDNA copy number as well as respiratory chain enzyme activities and levels. In contrast, dCMP+dTMP+THU therapy decreased life span of Tk2-/- animals compared to dCMP+dTMP. INTERPRETATION: Our studies demonstrate that deoxynucleoside substrate enhancement is a novel therapy, which may ameliorate TK2 deficiency in patients. Ann Neurol 2017;81:641-652.


Subject(s)
Antimetabolites/pharmacology , Deoxycytidine Monophosphate/pharmacology , Metabolism, Inborn Errors/drug therapy , Mitochondrial Diseases/drug therapy , Tetrahydrouridine/pharmacology , Thymidine Kinase/deficiency , Thymidine/pharmacology , Animals , Antimetabolites/administration & dosage , DNA, Mitochondrial/drug effects , Deoxycytidine Monophosphate/administration & dosage , Disease Models, Animal , Drug Therapy, Combination , Metabolism, Inborn Errors/enzymology , Mice , Mice, Transgenic , Mitochondrial Diseases/enzymology , Tetrahydrouridine/administration & dosage , Thymidine/administration & dosage
18.
Bull Exp Biol Med ; 166(1): 178-181, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30417285

ABSTRACT

We performed a comparative study of the formation of γН2АХ foci (a marker of DNA doublestrand breaks) in human bone marrow mesenchymal stem cells after 24-h incubation with 3Н-thimidin and tritium oxide with low specific activities (50-800 MBq/liter). The dependence of the number of γH2AX foci on specific activity of 3H-thymidine was described by a linear equation y=2.21+43.45x (R2=0.96), where y is the number of γH2AX foci per nucleus and x is specific activity in 1000 MBq/liter. For tritium oxide, the relationship was described by a linear equation y=2.52+6.70x (R2=0.97). Thus, the yield of DNA double-strand breaks after exposure to 3H-thymidine was 6.5-fold higher than after exposure to tritium oxide. Comparison of the effects of tritium oxide and X-ray radiation on the yield of DNA double-strand breaks showed that the relative biological efficiency of tritium oxide in a dose range of 3.78-60.26 mGy was 1.6-fold higher than that of X-ray radiation. Improvement of the methods of analysis of DNA double-strand breaks repair foci is highly promising in the context of creation of highly sensitive biodosimetry technologies for tritium compounds in humans.


Subject(s)
DNA Breaks, Double-Stranded/drug effects , DNA Breaks, Double-Stranded/radiation effects , Mesenchymal Stem Cells/drug effects , Mesenchymal Stem Cells/metabolism , Thymidine/pharmacology , Tritium/pharmacology , Water/pharmacology , X-Rays , Cells, Cultured , Humans , Mesenchymal Stem Cells/radiation effects
19.
Bull Exp Biol Med ; 164(3): 308-311, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29313227

ABSTRACT

Culturing of bone marrow cells in serum-free RPMI-1640 medium led to a decrease in the rate of DNA biosynthesis. Addition of HDL or their main protein component apolipoprotein A-I to the culture medium dose-dependently increased the rate of [3H]-thymidine incorporation into DNA. The maximum stimulation was achieved at HDL concentration of 80 µg/ml and apolipoprotein A-I concentration of 20 µg/ml. To identify the target-cells of apolipoprotein A-I, we used thymidine analogue 5-ethynyl-2'-deoxyuridine (EdU) that incorporates into cell DNA at the stage of replicative DNA synthesis (S phase) and can be detected by fluorescence microscopy. In bone marrow cell culture, apolipoprotein A-I stimulates the proliferation of monocyte (monoblasts, promonocytes) and granulocyte (myeloblasts, promyelocytes) progenitor cells, as well as bone marrow stromal cells.


Subject(s)
Apolipoprotein A-I/pharmacology , Bone Marrow Cells/drug effects , Cell Proliferation/drug effects , Granulocytes/drug effects , Mesenchymal Stem Cells/drug effects , Monocytes/drug effects , Animals , Apolipoprotein A-I/isolation & purification , Bone Marrow Cells/cytology , Bone Marrow Cells/immunology , Culture Media, Serum-Free/chemistry , DNA/biosynthesis , Deoxyuridine/analogs & derivatives , Deoxyuridine/metabolism , Deoxyuridine/pharmacology , Dose-Response Relationship, Drug , Granulocytes/cytology , Granulocytes/immunology , Humans , Lipoproteins, HDL/chemistry , Lipoproteins, HDL/pharmacology , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/immunology , Monocytes/cytology , Monocytes/immunology , Primary Cell Culture , Rats , Rats, Wistar , Thymidine/metabolism , Thymidine/pharmacology , Tritium
20.
Bioorg Chem ; 70: 44-56, 2017 02.
Article in English | MEDLINE | ID: mdl-27955923

ABSTRACT

Thymidine phosphorylase (TP) catalyzes the cleavage of thymidine into thymine and 2-deoxy-α-d-ribose-1-phosphate. Elevated activity of TP prevents apoptosis, and induces angiogenesis which ultimately leads to tumor growth and metastasis. Critical role of TP in cancer progression makes it a valid target in anti-cancer research. Discovery of small molecules as TP inhibitors is vigorously pursued in cancer therapy. In the present study, we functionalized thymidine as benzoyl ester to synthesize compounds 3-16. In vitro evaluation of thymidine esters for their thymidine phosphorylase inhibition activity was subsequently carried out. Compounds 4, 10, 14, and 15 showed good activities with lower IC50 values than the standard, 7-deazaxanthine (IC50=41.0±1.63µM). Among them, compound 14 showed five folds higher activity (IC50=7.5±0.8µM), while 4 (IC50=18.5±1.0µM) and 10 (IC50=18.8±1.2µM) showed two folds higher activity than the standard. Compound 15 showed slightly better activity (IC50=33.3±1.5µM) to the standard. Potent compounds were further subjected to kinetic and molecular docking studies to identify their mode of inhibition, and to study their interactions with the protein at atomic level, respectively. All active compounds were non-cytotoxic to mouse fibroblast 3T3 cell line. These results identify thymidine esters as substrate analogue (substrate-like) inhibitors of angiogenic enzyme thymidine phosphorylase for further studies.


Subject(s)
Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Thymidine Phosphorylase/antagonists & inhibitors , Thymidine/analogs & derivatives , Thymidine/pharmacology , 3T3 Cells , Animals , Escherichia coli/enzymology , Esters/chemistry , Esters/pharmacology , Humans , Mice , Molecular Docking Simulation , Thymidine Phosphorylase/chemistry , Thymidine Phosphorylase/metabolism , Xanthines/chemistry , Xanthines/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL